Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; IL13RA2 Positive; Metastatic Melanoma; Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV; Melanoma; Uveal Melanoma; Acral Melanoma; Neuroendocrine Tumors; Paraganglioma; Adrenocortical Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer; Breast Cancer; Lung Adenocarcinoma; Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine Phosphate; Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells; Drug: Recombinant Interleukin-2
Sponsors: Jonsson Comprehensive Cancer Center; City of Hope National Medical Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 23, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments